Articles

New Formulation of Levoleucovorin Approved
FDA Approvals, News & Updates
June 2011, Vol 2, No 3
A new, ready-to-use (RTU) injectable formulation of the folate analog levoleucovorin (Fusilev; Spectrum Pharmaceuticals) received FDA approval.
Read More
Sunitinib Second New Drug for Pancreatic Neuroendocrine Tumors
FDA Approvals, News & Updates
June 2011, Vol 2, No 3
Sunitinib (Sutent; Pfizer) is the second new option for the treatment of metastasized or unresectable locally advanced progressive pancreatic neuroendocrine cancerous tumors.
Read More
Vandetanib First Drug Indicated for Medullary Thyroid Cancer
FDA Approvals, News & Updates
June 2011, Vol 2, No 3
The US Food and Drug Administration (FDA) approved the orphan drug vandetanib (trade name pending; AstraZeneca), a tyrosine kinase inhibitor, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease.
Read More

Page 316 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.